Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be SignificantJuan Berenguer, Antonio Rivero‐Juárez, Manuel Márquez et al.|Open Forum Infectious Diseases|2018Cited by 28
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019Chiara Fanciulli, Juan Berenguer, Carmen Busca et al.|HIV Medicine|2022Cited by 28
HIV/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018Leire Pérez‐Latorre, Juan Berenguer, Rafael Micán et al.|Eurosurveillance|2021Cited by 19
Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIVRamón Teira, Juan Berenguer, Helena Díaz-Cuervo et al.|PLoS ONE|2021Cited by 10
Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish CohortRamón Teira, Adrián Curran, Helena Díaz-Cuervo et al.|Infectious Diseases and Therapy|2022Cited by 6